Suppr
超能文献

Benralizumab for Chronic Spontaneous Urticaria.

作者信息

Bernstein Jonathan A, Singh Umesh, Rao Marepalli B, Berendts Karen, Zhang Xiang, Mutasim Diya

机构信息

University of Cincinnati College of Medicine, Cincinnati, OH

Bernstein Clinical Research Center, Cincinnati, OH.

出版信息

N Engl J Med. 2020 Oct 1;383(14):1389-1391. doi: 10.1056/NEJMc2016395.

DOI:10.1056/NEJMc2016395

PMID:32997916

Abstract

摘要

相似文献

Benralizumab for Chronic Spontaneous Urticaria.

N Engl J Med. 2020 Oct 1;383(14):1389-1391. doi: 10.1056/NEJMc2016395.

Benralizumab for -Negative Hypereosinophilic Syndrome.

N Engl J Med. 2019 Apr 4;380(14):1336-1346. doi: 10.1056/NEJMoa1812185.

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8.

Benralizumab: for asthma, not yet for COPD.

Lancet Respir Med. 2014 Nov;2(11):862-863. doi: 10.1016/S2213-2600(14)70225-5. Epub 2014 Oct 8.

How relevant are eosinophils to chronic spontaneous urticaria? No evidence of clinical benefit from eosinophil depletion with benralizumab.

Br J Dermatol. 2024 Jul 16;191(2):153-154. doi: 10.1093/bjd/ljae165.

Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.

Allergy Asthma Proc. 2019 Nov 1;40(6):485-489. doi: 10.2500/aap.2019.40.4277.

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22.

Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):1007-1013. doi: 10.1080/17425255.2017.1359253. Epub 2017 Jul 24.

Biologic pathways for chronic spontaneous urticaria and their regulation by benralizumab.

Allergy. 2022 Dec;77(12):3687-3689. doi: 10.1111/all.15493. Epub 2022 Sep 8.

Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.

Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15.

引用本文的文献

[Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications].

Rev Fac Cien Med Univ Nac Cordoba. 2024 Dec 13;81(4):804-823. doi: 10.31053/1853.0605.v81.n4.44413.

Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.

Biomedicines. 2024 Jul 10;12(7):1531. doi: 10.3390/biomedicines12071531.

Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.

Arch Dermatol Res. 2024 May 25;316(6):261. doi: 10.1007/s00403-024-02966-6.

Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.

Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.

Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment.

Curr Pharm Des. 2024;30(23):1787-1790. doi: 10.2174/0113816128300373240514072201.

Targeted therapy for immune mediated skin diseases. What should a dermatologist know?

An Bras Dermatol. 2024 Jul-Aug;99(4):546-567. doi: 10.1016/j.abd.2023.10.002. Epub 2024 Mar 22.

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.

Nat Rev Drug Discov. 2023 Sep;22(9):743-767. doi: 10.1038/s41573-023-00750-1. Epub 2023 Aug 1.

Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.

Semin Immunol. 2023 Sep;69:101799. doi: 10.1016/j.smim.2023.101799. Epub 2023 Jul 4.

Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review.

Dermatol Ther (Heidelb). 2023 Aug;13(8):1647-1660. doi: 10.1007/s13555-023-00972-6. Epub 2023 Jun 29.

Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success.

Dermatol Ther (Heidelb). 2023 Aug;13(8):1629-1646. doi: 10.1007/s13555-023-00955-7. Epub 2023 Jun 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Benralizumab for Chronic Spontaneous Urticaria.

N Engl J Med. 2020 Oct 1;383(14):1389-1391. doi: 10.1056/NEJMc2016395.

Benralizumab for -Negative Hypereosinophilic Syndrome.

N Engl J Med. 2019 Apr 4;380(14):1336-1346. doi: 10.1056/NEJMoa1812185.

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8.

Benralizumab: for asthma, not yet for COPD.

Lancet Respir Med. 2014 Nov;2(11):862-863. doi: 10.1016/S2213-2600(14)70225-5. Epub 2014 Oct 8.

How relevant are eosinophils to chronic spontaneous urticaria? No evidence of clinical benefit from eosinophil depletion with benralizumab.

Br J Dermatol. 2024 Jul 16;191(2):153-154. doi: 10.1093/bjd/ljae165.

Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.

Allergy Asthma Proc. 2019 Nov 1;40(6):485-489. doi: 10.2500/aap.2019.40.4277.

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22.

Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):1007-1013. doi: 10.1080/17425255.2017.1359253. Epub 2017 Jul 24.

Biologic pathways for chronic spontaneous urticaria and their regulation by benralizumab.

Allergy. 2022 Dec;77(12):3687-3689. doi: 10.1111/all.15493. Epub 2022 Sep 8.

Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.

Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15.

引用本文的文献

[Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications].

Rev Fac Cien Med Univ Nac Cordoba. 2024 Dec 13;81(4):804-823. doi: 10.31053/1853.0605.v81.n4.44413.

Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.

Biomedicines. 2024 Jul 10;12(7):1531. doi: 10.3390/biomedicines12071531.

Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.

Arch Dermatol Res. 2024 May 25;316(6):261. doi: 10.1007/s00403-024-02966-6.

Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.

Int J Mol Sci. 2024 May 9;25(10):5164. doi: 10.3390/ijms25105164.

Targeted Biologic Therapies in Chronic Prurigo: The Evolving Landscape of Chronic Prurigo Treatment.

Curr Pharm Des. 2024;30(23):1787-1790. doi: 10.2174/0113816128300373240514072201.

Targeted therapy for immune mediated skin diseases. What should a dermatologist know?

An Bras Dermatol. 2024 Jul-Aug;99(4):546-567. doi: 10.1016/j.abd.2023.10.002. Epub 2024 Mar 22.

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.

Nat Rev Drug Discov. 2023 Sep;22(9):743-767. doi: 10.1038/s41573-023-00750-1. Epub 2023 Aug 1.

Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.

Semin Immunol. 2023 Sep;69:101799. doi: 10.1016/j.smim.2023.101799. Epub 2023 Jul 4.

Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review.

Dermatol Ther (Heidelb). 2023 Aug;13(8):1647-1660. doi: 10.1007/s13555-023-00972-6. Epub 2023 Jun 29.

Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success.

Dermatol Ther (Heidelb). 2023 Aug;13(8):1629-1646. doi: 10.1007/s13555-023-00955-7. Epub 2023 Jun 24.

Suppr超能文献

Benralizumab for Chronic Spontaneous Urticaria.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译